Martijn Lolkema
Overview
Explore the profile of Martijn Lolkema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Vries E, Ruschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, et al.
Cancer Med
. 2023 Apr;
12(11):12071-12083.
PMID: 37119523
The antibody-drug conjugate trastuzumab emtansine (T-DM1) is approved for human epidermal growth factor receptor 2 (HER2/ERBB2)-positive breast cancer. We aimed to study tumor HER2 expression and its effects on T-DM1...
2.
Mendelaar P, Robbrecht D, Rijnders M, de Wit R, de Weerd V, Deger T, et al.
Mol Oncol
. 2022 Feb;
16(10):2086-2097.
PMID: 35181986
Second-line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour-derived DNA (ctDNA) levels may guide patient stratification, provided...
3.
Rottey S, Clarke J, Aung K, Machiels J, Markman B, Heinhuis K, et al.
Clin Cancer Res
. 2021 Oct;
28(1):95-105.
PMID: 34615718
Purpose: To assess the safety and tolerability of BMS-986148, a mesothelin-directed antibody-drug conjugate (ADC) ± nivolumab, in patients with selected tumors. Patients And Methods: In an international phase I/IIa study...
4.
Jasu J, Tolonen T, Antonarakis E, Beltran H, Halabi S, Eisenberger M, et al.
Eur Urol Open Sci
. 2021 Aug;
30:47-62.
PMID: 34337548
Background: Systematic identification of data essential for outcome prediction in metastatic prostate cancer (mPC) would accelerate development of precision oncology. Objective: To identify novel phenotypes and features associated with mPC...
5.
Vitale S, Helmijr J, Gerritsen M, Coban H, van Dessel L, Beije N, et al.
BMC Cancer
. 2021 Mar;
21(1):315.
PMID: 33761899
Background: Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect...
6.
Sleijfer S, Lolkema M
Clin Cancer Res
. 2020 Jun;
26(15):3897-3898.
PMID: 32482905
A study was presented in which sarcomas were microinjected simultaneously with several drugs to study the pharmacodynamic response after resection. This platform may represent a future way of probing efficacy...
7.
Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi K, Bevan C, et al.
Eur Urol Oncol
. 2019 May;
1(2):151-159.
PMID: 31100240
Context: In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic monitoring and as...
8.
de Weger V, de Jonge M, Langenberg M, Schellens J, Lolkema M, Varga A, et al.
Br J Cancer
. 2018 Dec;
120(3):286-293.
PMID: 30585255
Background: This phase I, open-label, dose-escalation study evaluated the safety, pharmacokinetics and pharmacodynamics of combination therapy with the HDM2 inhibitor SAR405838 and the MEK1/2 inhibitor pimasertib administered orally once daily...
9.
MacDonald A, Priess M, Curran J, Guess J, Farutin V, Oosterom I, et al.
Mol Cancer Ther
. 2018 Nov;
18(2):245-256.
PMID: 30401693
Pancreatic cancer has an abysmal 5-year survival rate of 8%, making it a deadly disease with a need for novel therapies. Here we describe a multitargeting heparin-based mimetic, necuparanib, and...
10.
Mout L, de Wit R, Stuurman D, Verhoef E, Mathijssen R, de Ridder C, et al.
EBioMedicine
. 2017 Dec;
27:182-186.
PMID: 29276148
Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT) is the mainstay of (metastatic) prostate cancer therapy. Ultimately, the AR pathway will be re-activated despite castrate levels...